Carbamazepine for epilepsy. A controlled prospective evaluation.
D000328:Adult; D001772:Blood Cell Count; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004569:Electroencephalography; D004827:Epilepsy / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D010919:Placebos; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales
D010919:Placebos; D002220:Carbamazepine; D010672:Phenytoin; D010634:Phenobarbital